ACTU

0.22535.38%
RB

Roger B. Cohen

Member of Scientific Advisory Board

Dr. Roger B. Cohen, M.D., serves as Member of Scientific Advisory Board at Actuate Therapeutics, Inc. since October 2022. He served as Director of the Clinical Trials Office of the University of Virginia. Dr. Cohen serves as an Advisor and Consultant to the FDA at the Center for Biologics Evaluation and Research. He is Professor of Medicine in the Hematology-Oncology Division at the University of Pennsylvania and Associate Director for Clinical Research for the Abramson Cancer Center. He serves as Director of Phase I Trials of Fox Chase Cancer Center, where he also served as interim Medical Oncology Department Chair. He is a Medical Oncologist with expertise in the development and use of novel cancer treatments for a variety of cancers. He specializes in patients with a variety of cancers, including lung, head and neck, breast and thyroid cancer as well as cancers of unknown primary site. He is an expert in the design, conduct and analysis of all phases of clinical trials and has consulted for many pharmaceutical and biotechnology companies. Dr. Cohen served as Deputy Director for Division of Monoclonal Antibodies of the FDA Center for Biologics Evaluation and Research. Dr. Cohen serves as a Member of Scientific & Clinical Advisory Board at Scorpius Holdings, Inc. (formerly known as NightHawk Biosciences, Inc.) (formerly known as Heat Biologics, Inc.) He serves as a Member of the Advisory Board of Attenuon LLC and Member of the Scientific Advisory Board of Cerulean Pharma Inc. (formerly, Tempo Pharmaceuticals Inc). He served as a Scientific Advisor of Cavion LLC (formerly Tau Therapeutics LLC). Dr. Cohen served as a Member of the Clinical Advisory Board at Twin Butte Energy Ltd. He served as Member of the Scientific Advisory Board at Wilex AG. He served as a Member of The Medical Advisory Board - Small Molecules at Wilex AG. He was Professor of Medicine of Fox Chase Cancer Center. He is Associate Professor at the University of Virginia, Department of Medicine, Division of Haematology-Oncology. He completed internal medicine and hematology training at Mount Sinai Hospital (NY) followed by research fellowships at the Memorial Sloan-Kettering Cancer Center and National Institutes of Health and a medical oncology fellowship at the National Cancer Institute. He is the recipient of several awards including the FDA Special Recognition Award. Dr. Cohen received his Medical degree from Harvard Medical School.

Positions